SW
BIB icon

SlateStone Wealth’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

SlateStone Wealth’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,975
Closed -$258K – 172
2019
Q2 		$258K Buy
+4,975
New +$248K 0.07% 153

Other funds holding BIB

CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CAL
Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

SlateStone Wealth's BIB Position: Q3 2019 in Review

SlateStone Wealth sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2019, closing a stake of 4,975 shares — an estimated $258K sold.

SlateStone Wealth first reported a position in BIB in Q2 2019 and held it in 1 quarter. The position peaked at $258K in Q2 2019. 25 funds tracked by Wall St. Rank hold BIB as of Q3 2019.

  • SlateStone Wealth reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
  • SlateStone Wealth sold 4,975 ProShares Ultra NASDAQ Biotechnology shares in Q3 2019, an estimated $258K.
  • SlateStone Wealth first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2019 and held it in 1 quarter.
  • SlateStone Wealth's ProShares Ultra NASDAQ Biotechnology position peaked at $258K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2019.

Based on SlateStone Wealth's 13F filing for Q3 2019, filed 5 Nov 2019.